The estimated Net Worth of James A Mcnulty is at least $261 millier dollars as of 24 January 2014. James Mcnulty owns over 89,223 units of Inhibitor Therapeutics stock worth over $11,090 and over the last 19 years James sold INTI stock worth over $250,200.
Sign up
James Mcnulty INTI stock SEC Form 4 insiders trading
James has made over 11 trades of the Inhibitor Therapeutics stock since 2005, according to the Form 4 filled with the SEC. Most recently James exercised 89,223 units of INTI stock worth $272,130 on 24 January 2014.
The largest trade James's ever made was exercising 108,798 units of Inhibitor Therapeutics stock on 6 July 2012 worth over $294,843. On average, James trades about 15,754 units every 152 days since 2005. As of 24 January 2014 James still owns at least 138,622 units of Inhibitor Therapeutics stock.
You can see the complete history of James Mcnulty stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's James Mcnulty's mailing address?
James's mailing address filed with the SEC is C/O INHIBITOR THERAPUTICS, INC.,, 900 WEST PLATT ST, SUITE 200, TAMPA, FL, 33606.
Insiders trading at Inhibitor Therapeutics
Over the last 5 years, insiders at Inhibitor Therapeutics have traded over $0 worth of Inhibitor Therapeutics stock and bought 13,500 units worth $945 . The most active insiders traders include James A Mcnulty, W. Mark Watson et Samuel P Jr Sears. On average, Inhibitor Therapeutics executives and independent directors trade stock every 0 days with the average trade being worth of $1,080. The most recent stock trade was executed by Garrison J. Hasara on 2 December 2019, trading 13,500 units of INTI stock currently worth $945.
What does Inhibitor Therapeutics do?
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
What does Inhibitor Therapeutics's logo look like?
Complete history of James Mcnulty stock trades at Biodelivery Sciences International et Inhibitor Therapeutics
Inhibitor Therapeutics executives and stock owners
Inhibitor Therapeutics executives and other stock owners filed with the SEC include:
-
Nicholas Jon Virca,
Pres & CEO -
Garrison J. Hasara CPA, CPA,
CFO, Treasurer, Corp. Sec. & Chief Compliance Officer -
Pharma Ventures Pty Ltd May...,
-
Debra Peattie,
Director -
Robert Daniel Martin,
Director -
Garrison J. Hasara,
CFO and Treasurer -
Richard Dana Ono,
Director -
Nicholas J Virca,
President and CEO -
W. Mark Watson,
Director -
Michelle Yanez,
Director -
James A Mcnulty,
CHIEF FINANCIAL OFFICER -
Ronald E Ronald E Osman Irr...,
-
Samuel P Jr Sears,
Director -
Michael Allen Jerman,
Director